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Dr FriedrichM.Mohr (Leipzig, Germany). Dr Reardon, thank
you very much for this excellent presentation and also for
providing the report in advance, which only had the 150 patients
in writing compared with 338 patients right now in your talk,
which is, of course, something I could not review in advance.
I will focus on the 150 patients in your report. In this analysis,
you report the early and 1-year outcome of 150 patients with
severe aortic stenosis and aortoiliac and femoral stenosis. All
patients were treated using the transcatheter CoreValve system
for aortic valve replacement through an alternative route, which
was, in 70 times, the subclavian artery, or in 80 times, the direct
aortic approach.
All patients could be treated successfully. In some of the
patients, 2 valves were implanted. Perhaps you can expand on
that, whether it was 1 patient who received 2, a valve-in-valve,
or 2 patients. A number of 2.9 did not make any sense to me.
This is question 1.
By 30 days, the primary endpoint of death and major stroke had
occurred in 23 or 15% of the patients. You further reported that
death occurred in 17 patients or 11.3%, and major stroke in 11
or 17.5%. If you sum the data, 11 and 17, this does not equal 23.
This somehow does not fit together. So, I have a mathematical
problem.
The reported stroke rates seem to be greater compared with
those from other studies, such as the SAPIENAortic Bioprosthesis
European Outcome (SOURCE) Registry identified major access
complications associated with high 30-day mortality and/or the
German Aortic Valve Registry reporting on transapical access
implanting other alternative valves compared with the CoreValve.
Can you comment on that?2876 The Journal of Thoracic and Cardiovascular SurFinally, I congratulate you on the reported results in this
high-risk population. Although, a control group is lacking, the
published data from the past 10 years has proved the benefit
of TAVR versus medical treatment. It would be interesting to
randomly compare all alternative routes, including the transapical
approach.
Dr Reardon. Thank you, Dr Mohr.
As far as the question about the SOURCE registry and GARY,
of course, these are registries with self-reported data. In the
CoreValve trial, we already knew that the Food and Drug Admin-
istration was keenly interested in stroke; thus, every patient in the
CoreValve Pivotal Trial had a National Institutes of Health stroke
scale assessment before treatment and a National Institutes of
Health stroke scale assessment immediately after treatment. If
any changes at all were found, the patient underwent a neurologic
evaluation and imaging studies.
Thus, we actually studied the data a lot more than registries
have tended to or that the PARTNER trial did because the study
of the data was all retrospective. So, it was not surprising if we
had a greater incidence of strokes, because if you look harder,
you tend to find more.
Additionally, transapical access was not allowed in the
nonoperable extreme risk patients in the PARTNER B trial,
and most of the patients in the registries you mentioned were
high- to intermediate-risk patients. These were not high-risk
patients as you stated but extreme risk patients comparable to those
in the PARTNER B trial.
I believe the 339 additional patients in the continued access
group were included in the report, and I apologize for any
confusion. The number of patients who required the use of 2 valves
was 2.9% and included those with a valve-in-valve and those who
had had the first valve removed and a second valve placed, ending
with only 1 valve in place but 2 valves used.
The question about death or major stroke at 30 days occurring in
23 patients, death as an isolated event in 17 and major stroke as an
isolated event in 11 does add up, because some patients
experienced both major stroke and death. They were therefore
counted individually in each the death and major stroke isolated
categories but only once in the death or major stroke group,
because this is an ‘‘or’’ statement.
Dr Mohr. Okay.
Dr Reardon. However, there are some differences, and, again,
I think, 1 of the differences, when you try to compare our study to
registries such as SOURCE or GARYor the France II or UK, is that
this was really a single-arm longitudinal study that demands data
input. It requires outside monitoring. It requires outside clinical
events review. It demands outside core laboratories, and it fits all
the criteria of a very strict Food and Drug Administration trial.
So it does make it a unique way of looking at this.
Dr Mohr. Thank you.gery c December 2014
